Press Releases

Date Title
Toggle Summary Kura Oncology to Present at Bank of America Merrill Lynch Health Care Conference
SAN DIEGO , May 08, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, is scheduled to present
Toggle Summary Kura Oncology Reports First Quarter 2019 Financial Results and Highlights Upcoming Milestones
– Registration-directed trial of tipifarnib in HRAS mutant HNSCC continues on track – – Data from ongoing Phase 2 trial of tipifarnib in CXCL12-driven PTCL accepted for oral presentations at EHA and ICML next month – – Data from ongoing Phase 2 trial of tipifarnib in HRAS mutant HNSCC and other
Toggle Summary Kura Oncology to Report First Quarter 2019 Financial Results
SAN DIEGO , April 30, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report first quarter 2019 financial results after the close of U.S.
Toggle Summary Kura Oncology Identifies Farnesylated Proteins Associated with CXCL12 Expression, Potential Biomarker of Clinical Benefit from Tipifarnib in Lymphoma Indications
– Tipifarnib is a farnesyl transferase inhibitor that downregulates CXCL12 – – Gene expression of the exclusively farnesylated RHOE and PRICKLE2 proteins associated with CXCL12 expression – – Pre-treatment tumor CXCL12 expression identified as a potential biomarker of clinical benefit in patients
Toggle Summary Kura Oncology to Participate in Two Upcoming Investor Conferences
SAN DIEGO , March 06, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, is scheduled to
Toggle Summary Kura Oncology Reports Fourth Quarter and Full Year 2018 Financial Results
– Registration-directed trial of tipifarnib in HRAS mutant HNSCC underway – – Data from three ongoing Phase 2 trials of tipifarnib anticipated this year – – Third drug candidate menin-MLL inhibitor KO-539 poised to enter clinic next quarter – – $179 million in cash, cash equivalents and investments
Toggle Summary Kura Oncology Announces FDA Clearance of Investigational New Drug Application for Menin-MLL Inhibitor KO-539
– KO-539 is a potent, selective small molecule inhibitor of the menin-MLL interaction – – Robust anti-tumor activity observed in mixed lineage leukemias rearranged and oncogenic driver mutations in genes such as NPM1 – – Phase 1 clinical trial in relapsed or refractory AML expected to initiate next
Toggle Summary Kura Oncology to Report Fourth Quarter and Full Year 2018 Financial Results
SAN DIEGO , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report fourth quarter and full year 2018 financial results after the close of
Toggle Summary Kura Oncology to Present at SVB Leerink Global Healthcare Conference
SAN DIEGO , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, is scheduled to
Toggle Summary Kura Oncology Reports Clinical Activity of Tipifarnib in Subsets of Pancreatic Cancer Associated with High CXCL12 Expression
– Tipifarnib is a CXCL12 pathway inhibitor that may provide clinical benefit in subsets of patients with pancreatic cancer – – Analysis of a previously conducted, randomized Phase 3 trial reveals patients with lymph node or liver metastases and those with no abdominal pain appear more likely to